Oh Hyeon-Muk, Kim Eun-Ji, Bae Hye-Ri, Cho Jung-Hyo, Son Chang-Gue, Lee Nam-Hun
Daejeon Korean Medicine Hospital, Daejeon University, Daejeon, Republic of Korea.
East-West Cancer Center, Cheonan Korean Medicine Hospital, Daejeon University, Daejeon, Republic of Korea.
Front Oncol. 2023 Feb 9;13:1106827. doi: 10.3389/fonc.2023.1106827. eCollection 2023.
Primary hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths, especially in Asian countries. As a practical treatment option, transarterial chemoembolization (TACE) has been well applied; however, its limited efficacy remains challenging. This study analyzed the adjuvant effects of herbal medicine on TACE to determine whether it improves clinical outcomes in patients with HCC.
A systematic review and meta-analysis was performed to compare the adjuvant effects of herbal medicine on TACE versus TACE therapy alone. We searched the literature from eight databases since January 2011.
Twenty-five studies involving 2,623 participants were selected. The adjuvant therapy of herbal medicine on TACE improved the overall survival at 0.5 years (OR = 1.70; 95% CI 1.21-2.38), 1 year (OR = 2.01; 95% CI 1.65-2.46), 2 years (OR = 1.83; 95% CI 1.20-2.80), and 3 years (OR = 1.90; 95% CI 1.25-2.91). The combination therapy also increased the tumor response rate (OR = 1.84; 95% CI 1.40-2.42).
Despite the unsatisfactory quality of the included studies, the adjuvant therapy of herbal medicine on TACE may provide survival benefits to patients with HCC.
http://www.crd.york.ac.uk/PROSPERO, identifier (376691).
原发性肝细胞癌（HCC）是癌症相关死亡的主要原因之一，尤其是在亚洲国家。作为一种实用的治疗选择，经动脉化疗栓塞术（TACE）已得到广泛应用；然而，其疗效有限仍然是一个挑战。本研究分析了中药对TACE的辅助作用，以确定其是否能改善HCC患者的临床结局。
进行了一项系统评价和荟萃分析，以比较中药对TACE与单纯TACE治疗的辅助作用。我们检索了自2011年1月以来八个数据库中的文献。
选取了25项研究，涉及2623名参与者。中药对TACE的辅助治疗在0.5年（OR = 1.70；95%CI 1.21 - 2.38）、1年（OR = 2.01；95%CI 1.65 - 2.46）、2年（OR = 1.83；95%CI 1.20 - 2.80）和3年（OR = 1.90；95%CI 1.25 - 2.91）时提高了总生存率。联合治疗还提高了肿瘤反应率（OR = 1.84；95%CI 1.40 - 2.42）。
尽管纳入研究的质量不尽人意，但中药对TACE的辅助治疗可能为HCC患者带来生存益处。
